Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Alexion Pharma target lowered to $177 at RBC Capital Mkts — 2017 will probably be OK; '1210 is ALXN's future (130.39)RBC Capital Mkts lowers their ALXN tgt to $177 from $187. Some concerns about Alexion's near-term direction were probably alleviated today: 2017 isn't expected to be the bad year many feared. However, they see Alexion's future as heavily leveraged on one molecule ('1210) and remain concerned about the lack of data disclosure: while two new Phase IIIs were just announced, they haven't yet seen any data from PNH/aHUS patients treated with 3000-3600mg of q8w 1210.</td> </tr></table>"